Nadim M. Rayess

Nadim Rayess practices at Retina Associates of Florida, P.A. in Tampa, Florida.

Nadim Rayess' NPI, 1144615212, was assigned on April 5, 2015. Nadim Rayess graduated from American University of Beirut Faculty of Medicine in 2013. Nadim Rayess' California license number on file is A151249.

Nadim Rayess' primary practice is Retina Associates of Florida, P.A., at 602 S Macdill Ave, Tampa, FL 33609 in Hillsborough County. The practice phone is (813) 875-6373.

Nadim Rayess' primary practice is Retina Associates of Florida, P.A. in Tampa, Florida. Dmand AI also links Nadim Rayess to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Nadim Rayess practices. Vendor and product names are available with a free account.

Ophthalmology is Nadim Rayess' primary specialty in the NPI Registry, under taxonomy code 207W00000X. Nadim Rayess is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Nadim Rayess' licenses on file in 3 states: California, Florida and Michigan.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, glaucoma, hypertensive retinopathy, laser destruction of retinal or choroid lesions, retinal detachment and retinal occlusion among the conditions Nadim Rayess treats.

CMS data shows 38,321 Medicare services from Nadim Rayess across 15 procedure codes in 2024, for 513 Medicare patients. Medicare paid $1,339,357 for them. Every service was in an office.

CMS counts 513 Medicare patients who saw Nadim Rayess in 2024. The largest group is 65 to 74, with 195 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 2% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Nadim Rayess' median patient age at 66, with 54% women.

In 2024, Nadim Rayess wrote 263 Medicare Part D claims for 70 patients. 55% of them were for generic drugs. CMS names the drug for 208 of them, across 8 drugs with 11 or more claims each, at $5,984 in total drug cost. In 2023, CMS named 147 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Nadim Rayess for performance year 2024, reported as part of a group. Nadim Rayess accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 37 papers to Nadim Rayess, published from 2014 to 2024. 2020 was the busiest year, with 6. The most frequent topics are Angiogenesis Inhibitors, Intravitreal Injections and Tomography, Optical Coherence. Nadim Rayess has published most often in JAMA Ophthalmol. Nadim Rayess' most frequent co-authors are Ehsan Rahimy, MD, Prithvi Mruthyunjaya, MD and Allen C. Ho, MD.

CMS Open Payments shows 229 general payments to Nadim Rayess from 26 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 67% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $7,469.

Nadim Rayess graduated from American University of Beirut Faculty of Medicine in 2013.

Nadim Rayess is in network with 17 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.